Efficacy and safety of empagliflozin in combination with insulin in Chinese patients with type 2 diabetes and insufficient glycaemic control: A Phase III, randomised, double-blind, placebo-controlled, parallel study.
Li-Nong JiYibin LuQi Fu LiLiujun FuYong LuoTao LeiLing LiShandong YeBimin ShiXiyan LiThomas MeinickePublished in: Diabetes, obesity & metabolism (2023)
In Chinese patients with T2DM, empagliflozin combined with insulin ± OADs improved glycaemic control and was well tolerated, without increased risk of hypoglycaemia. This article is protected by copyright. All rights reserved.